iPSC-DERIVED NK CELL FOR LYMPHOMA TREATMENT
AssigneeFate Therapeutics, Inc.
InventorsBahram VALAMEHR, ALAN WILLIAMS, JODE GOODRIDGE
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for use in cancer immunotherapies. In various embodiments, the compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Claims23
A method of treating a subject having lymphoma, comprising:
- administering to the subject at least a first cycle of an adoptive cell therapy product, with the first cycle comprising one or more doses of the adoptive cell therapy product administered in a first effective amount at a preselected frequency, and with an option of administering one or more additional cycles with one or more doses in a second effective amount, during a course of treatment over a period of time;
- wherein the first and the second effective amounts are the same or different;
- wherein the adoptive cell therapy product comprises an engineered natural killer (NK) lineage cell comprising CD19-CAR (chimeric antigen receptor) expression, 41BB-ADR expression, exogenous CD16 expression, IL15RF expression, and CD38 knockout;
- and
- wherein the lymphoma expresses CD19.
Dependencies are inferred from the claim text.